PillInsulin Aspart
Brands: Novolog · Insulin Aspart
3 active makers
soon
soon
soon
soon
US acquisition costNADAC · per unit
Average across 6 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
Who makes it3 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Novo Nordisk | unknown | 12 | SUPPLYING |
| A-S Medication Solutions | unknown | 5 | SUPPLYING |
| REMEDYREPACK INC. | repackager | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jul 21, 2025RESOLVEDShortage resolved: Insulin Aspart Injection (Novo Nordisk, Inc.)
Insulin Aspart Injection — reported in shortage by Novo Nordisk, Inc.. Therapeutic category: Endocrinology/Metabolism.
- Jul 21, 2025SHORTAGEDrug shortage: Insulin Aspart Injection (Novo Nordisk, Inc.)
Insulin Aspart Injection — reported in shortage by Novo Nordisk, Inc.. Therapeutic category: Endocrinology/Metabolism.
- Mar 22, 2021RECALLRecall (Class I): NovoLog (Insulin aspart) Injection, 100 units/mL (U-100), One 10 mL multi-dose vial, Sample. Not for Resale, Rx Only, M…
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. — Recalling firm: Novo Nordisk Inc — Nationwide in the USA
- Mar 22, 2021RECALLRecall (Class I): NovoLog FlexPen (insulin aspart) Injection, 100 units/mL, 3 mL Prefilled Insulin Syringe pen, Sample. Not for Resale, R…
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. — Recalling firm: Novo Nordisk Inc — Nationwide in the USA